Effectiveness and Safety of Immunomodulators With Anti-Tumor Necrosis Factor Therapy in Crohn's Disease - Wikidata - wikimedia - TriplyDB

Effectiveness and Safety of Immunomodulators With Anti-Tumor Necrosis Factor Therapy in Crohn's Disease

Effectiveness and Safety of Immunomodulators With Anti-Tumor Necrosis Factor Therapy in Crohn's Disease

http://www.wikidata.org/entity/Q35763489

about

How should immunomodulators be optimized when used as combination therapy with anti-tumor necrosis factor agents in the management of inflammatory bowel disease?Invasive fungal infections in pediatric patients treated with tumor necrosis alpha (TNF-α) inhibitors Combination therapy for inflammatory bowel disease Methotrexate for Inflammatory Bowel Diseases - New Developments Early anti-TNF/immunomodulator therapy is associated with better long-term clinical outcomes in Asian patients with Crohn's disease with poor prognostic factors Risk of Herpes Zoster in Individuals on Biologics, Disease-Modifying Antirheumatic Drugs, and/or Corticosteroids for Autoimmune Diseases: A Systematic Review and Meta-Analysis.Pharmacology and Optimization of Thiopurines and Methotrexate in Inflammatory Bowel Disease.Postoperative prophylaxis in Crohn's disease after intestinal resection: a retrospective analysis.A safety assessment of anti-tumor necrosis factor alpha therapy for treatment of Crohn's disease.Intestinal Dilation and Platelet:Albumin Ratio Are Predictors of Surgery in Stricturing Small Bowel Crohn's Disease Considerations, challenges and future of anti-TNF therapy in treating inflammatory bowel disease.Infection risk with biologic therapy in patients with inflammatory bowel disease.Effects of concomitant immunomodulators on the pharmacokinetics, efficacy and safety of adalimumab in patients with Crohn's disease or ulcerative colitis who had failed conventional therapy.Sequential Combination Therapy Versus Monotherapy: A Lack of Benefit in Time to Inflammatory Bowel Disease-Related Surgery.The benefit of combination therapy depends on disease phenotype and duration in Crohn's disease.Azathioprine dose reduction in inflammatory bowel disease patients on combination therapy: an open-label, prospective and randomised clinical trial.Increased Mortality Rates With Prolonged Corticosteroid Therapy When Compared With Antitumor Necrosis Factor-α-Directed Therapy for Inflammatory Bowel Disease.

P2860

Q26777409-29832979-B924-4981-B2EF-911E1DB4FB3B Q29302324-402BE1B9-514A-4744-83C1-84D59F69FBA3 Q33646452-B8C6C94F-E8FF-4816-86B2-BA0A5509A5C8 Q34518393-46603129-FC7A-49CE-98CB-ACEECFBD154B Q36380315-F42CFCF4-F63E-4258-AA9B-80DAF25E36A7 Q37484842-79B75219-2C83-40C4-BA39-64D6424B8443 Q38563075-D38B40F1-3ECE-47E8-B65F-C6DE8C053245 Q38608939-384D79E5-2B97-43B7-BC09-DE9B7D63A8BB Q38707864-5597AABA-A2C8-446E-979A-7D28233E33D8 Q38828253-D6104669-CEF0-48F3-9E8F-1FCF4D891655 Q38850063-73F390E1-8EFA-4EB8-820A-6FBCAF01AB99 Q39429997-C175B5C5-1071-4B1E-8033-F67165730565 Q42151036-F685F148-F4F3-49EC-96C7-D4C2907DE29A Q42616840-D810754C-7EF3-405B-B1D3-FEF5AC563B3F Q48194119-D7052826-19C2-4F6D-8EFC-947C06A8CCE5 Q48224314-8F6C5905-1EB3-4F88-822F-0B1EE0F4F6FB Q50037387-93FD965F-6060-4DCB-8B07-C12830280F91

P2860

Effectiveness and Safety of Immunomodulators With Anti-Tumor Necrosis Factor Therapy in Crohn's Disease

http://www.wikidata.org/entity/Q35763489

description

2015 nî lūn-bûn

@nan

2015年の論文

@ja

2015年論文

@yue

2015年論文

@zh-hant

2015年論文

@zh-hk

2015年論文

@zh-mo

2015年論文

@zh-tw

2015年论文

@wuu

2015年论文

@zh

2015年论文

@zh-cn

name

Effectiveness and Safety of Im ...... tor Therapy in Crohn's Disease

@ast

Effectiveness and Safety of Im ...... tor Therapy in Crohn's Disease

@en

type

label

Effectiveness and Safety of Im ...... tor Therapy in Crohn's Disease

@ast

Effectiveness and Safety of Im ...... tor Therapy in Crohn's Disease

@en

prefLabel

Effectiveness and Safety of Im ...... tor Therapy in Crohn's Disease

@ast

Effectiveness and Safety of Im ...... tor Therapy in Crohn's Disease

@en

P1433

Q35763489-8C21A339-D604-4B94-A7AD-9C265F64DAB1

P1476

Q35763489-9813A64F-4EA6-44FE-BA6A-25FE4D0B829E

P2093

Q35763489-24C82110-613F-47CA-AF09-CD57D8F5790B

Q35763489-2EE37C17-096D-4891-B96B-855AB4AB9119

Q35763489-32929319-C7F8-499B-BC49-7B320AF40A3E

Q35763489-8835E5BA-FF1D-4E6C-9D97-1CC2F9554FBA

Q35763489-94E8F812-8D62-432A-BC1B-C95632BC9406

Q35763489-A254F621-0CC5-48A9-BCD3-D4D3D460F6C6

Q35763489-D074DEAE-8A88-40F6-B65A-E13979B96C61

Q35763489-E103BD54-4D2F-4A4D-9A18-4450DD9EE536

Q35763489-E4A05FDC-0F14-40FF-8DBD-F873EEFC1A92

Q35763489-EE4DC7E1-B1FE-48D4-B48C-A2DF90F37D8F

P2860

Q35763489-022DD507-46E0-48B0-90A8-D2AB51C49FD4

Q35763489-0E4034AE-7340-46B5-9F41-E57A9541C727

Q35763489-13CEA296-8E77-489D-9A77-8E0C144D3208

Q35763489-1A34DA81-A22B-4300-A3D2-78957E61C6D6

Q35763489-23DE3478-674B-4AE3-8CF9-92829F1DE6C4

Q35763489-261C9C26-3860-4A10-9014-B9692C20B782

Q35763489-28C9FC94-511B-4AB1-9AAC-E98F0D8608EA

Q35763489-493B9BAB-8C9B-4E38-8FD3-808A72C579FE

Q35763489-51E8A76D-A696-4486-B44E-DBF854B62F71

Q35763489-54105318-9F6D-44F7-8302-97FC5BAAB7E9

P304

Q35763489-FB46369D-9043-49F0-9618-9158460695F1

P31

Q35763489-26D92E38-FEB3-4678-8BF5-FF7843037769

P356

Q35763489-FB42D219-6777-4751-BDAA-AF7AAC6797D9

P407

Q35763489-E3C79E99-3F2A-4615-88D9-4B961BE73E6C

P433

Q35763489-056068FA-DCBF-4E8F-8BE9-4DB908932042

P478

Q35763489-4337CBDC-32C2-4B0F-B42E-3727E46A1940

P577

Q35763489-1571CA64-E11B-44FA-AB72-2255EAD39F9D

P698

Q35763489-F466FED4-14C6-4B6A-918E-1DA06114D0E8

P921

Q35763489-F00C68CF-BB6A-4655-86F0-4566C3C4A75F

P932

Q35763489-E236CCC6-AE94-4AAB-9A56-0A2F968C1A45

P356

J.CGH.2015.02.017

P1433

Clinical Gastroenterology and Hepatology

P1476

Effectiveness and Safety of Im ...... tor Therapy in Crohn's Disease

@en

P2093

Colleen M Brensinger

http://www.w3.org/2001/XMLSchema#string

Elizabeth Delzell

http://www.w3.org/2001/XMLSchema#string

Fenglong Xie

http://www.w3.org/2001/XMLSchema#string

James D Lewis

http://www.w3.org/2001/XMLSchema#string

Jeffrey R Curtis

http://www.w3.org/2001/XMLSchema#string

Jie Zhang

http://www.w3.org/2001/XMLSchema#string

Kevin Haynes

http://www.w3.org/2001/XMLSchema#string

Lang Chen

http://www.w3.org/2001/XMLSchema#string

Mark T Osterman

http://www.w3.org/2001/XMLSchema#string

Meenakshi Bewtra

http://www.w3.org/2001/XMLSchema#string

P2860

Increased risk of lymphoma among inflammatory bowel disease patients treated with azathioprine and 6-mercaptopurine

Maintenance infliximab for Crohn's disease: the ACCENT I randomised trial

Infliximab maintenance therapy for fistulizing Crohn's disease

Cancer risk with tumor necrosis factor alpha (TNF) inhibitors: meta-analysis of randomized controlled trials of adalimumab, etanercept, and infliximab using patient level data.

Improved comorbidity adjustment for predicting mortality in Medicare populations.

Non-viral opportunistic infections in new users of tumour necrosis factor inhibitor therapy: results of the SAfety Assessment of Biologic ThERapy (SABER) study.

Effectiveness of concomitant immunosuppressive therapy in suppressing the formation of antibodies to infliximab in Crohn's disease.

Initiation of tumor necrosis factor-α antagonists and the risk of hospitalization for infection in patients with autoimmune diseases.

Brief report: incidence of selected opportunistic infections among children with juvenile idiopathic arthritis.

Comparative effectiveness of infliximab and adalimumab for Crohn's disease.

P304

1293-1301.e5; quiz e70, e72

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1016/J.CGH.2015.02.017

http://www.w3.org/2001/XMLSchema#string

P407

P433

7

http://www.w3.org/2001/XMLSchema#string

P478

13

http://www.w3.org/2001/XMLSchema#string

P577

2015-02-24T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

25724699

http://www.w3.org/2001/XMLSchema#string

P921

Crohn's disease

P932

4475667

http://www.w3.org/2001/XMLSchema#string